Medtronic Launches Trial Of Tricuspid Version Of Intrepid Transcatheter Valve
The company is sponsoring an early feasibility trial of the Intrepid transcatheter valve replacement system for patients with severe tricuspid regurgitation.
You may also be interested in...
The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.
Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscupid valve regurgitation, competing against Abbott’s newly CE-marked TriClip.
A new trial will evaluate the feasibility of implanting Medtronic's Intrepid transcatheter mitral valve replacement system through a transfemoral approach after the Intrepid TMVR study showed the feasibility of implanting Intrepid through the transapical approach.